Odyssey Group Intl Inc. (ODYY)

Sorry, no known transcripts

Recent filings

Entry into a Material Definitive - Aug. 18, 2023

Jonathan D. Lutz just provided an update on share ownership of Odyssey Group Intl Inc. - July 28, 2023

Entry into a Material Definitive - July 7, 2023

Other Material - June 28, 2023

Odyssey Group Intl Inc. Just Filed Its Quarterly Report: Note 8.       Net Lo... - June 14, 2023

Entry into a Material Definitive - April 4, 2023

Odyssey Group Intl Inc. Just Filed Its Quarterly Report: Note 8.       Net Lo... - March 17, 2023

Odyssey Group Intl Inc.'s President & CEO was just granted 500,000 restricted shares - Jan. 13, 2023

Odyssey Group Intl Inc. director was just granted 500,000 restricted shares - Jan. 13, 2023

Odyssey Group Intl Inc.'s CFO was just granted 500,000 restricted shares - Jan. 13, 2023

Odyssey Group Intl Inc. director was just granted 500,000 restricted shares - Jan. 13, 2023

Odyssey Group Intl Inc. director was just granted 500,000 restricted shares - Jan. 13, 2023

Submission of Matters to a Vote of Security - Jan. 13, 2023

Departure of Directors or Certain - Jan. 6, 2023

Entry into a Material Definitive - Jan. 3, 2023

Odyssey Group Intl Inc. Just Filed Its Quarterly Report: Note 7. Net Loss Per... - Dec. 14, 2022

Other definitive proxy statements - Nov. 29, 2022

Odyssey Group Intl: Odyssey Health, Inc. Provides Update On Company And The Progress Of Concussion Drug Development - Nov. 25, 2022

Other Material - Nov. 23, 2022

Entry into a Material Definitive - Nov. 23, 2022

Odyssey Group Intl Inc. insider was just granted 600,000 options - Nov. 23, 2022

Odyssey Group Intl Inc. insider just declared 150,000 options - Nov. 23, 2022

Odyssey Group Intl Inc. insider was just granted 600,000 options - Nov. 23, 2022

Odyssey Group Intl Inc. insider just declared ownership of no shares of Odyssey Group Intl Inc. - Nov. 23, 2022

Other preliminary proxy statements - Nov. 18, 2022

Odyssey Group Intl: Odyssey Health Inc. Strengthens Commitment To Odyssey Neuropharma Through Expansion Of Executive Team - Nov. 4, 2022

Odyssey Group Intl: Odyssey Health Inc. Files Full Us Patent Application On Novel Breath-Propelled Intranasal Brain-Drug Delivery Device - Nov. 1, 2022

Odyssey Group Intl Inc. Just Filed Its Annual Report: Net loss per share  ... - Oct. 31, 2022

Odyssey Group Intl Inc. insider was just granted 1,000,000 options - Oct. 19, 2022

Odyssey Group Intl Inc.'s Chief Financial Officer was just granted 500,000 options - Oct. 19, 2022

Entry into a Material Definitive - Oct. 3, 2022

Odyssey Group Intl: Odyssey Health, Inc. Announces Successful Completion Of Phase I Clinical Trial For Concussion Drug - Sept. 30, 2022

Odyssey Group Intl Inc.'s President & CEO just disposed of 1,500,000 shares - Sept. 15, 2022

Other Material - Sept. 15, 2022

Odyssey Group Intl: Odyssey Health Achieves Positive Safety Outcomes For Concussion Drug In Multiple Ascending Dosing Trial - Aug. 18, 2022

Odyssey Group Intl Inc. just filed a prospectus, suggesting it plans to soon issue some securities - Aug. 9, 2022

General form for registration of securities under the Securities Act of 1933 - July 29, 2022

Odyssey Group Intl Inc. Just Filed Its Quarterly Report: Note 9.       Net Lo... - June 14, 2022

Odyssey Group Intl Inc. insider just picked up 1,000,000 shares - June 14, 2022

Notice of Exempt Offering of Securities, item 06b - June 13, 2022

Odyssey Group Intl Inc. director was just granted 500,000 options - June 8, 2022

Odyssey Group Intl Inc. insider was just granted 100,000 options - June 8, 2022

Odyssey Group Intl Inc.'s President/CEO was just granted 750,000 options - June 8, 2022

Odyssey Group Intl Inc.'s Chief Financial Officer was just granted 600,000 options - June 8, 2022

Odyssey Group Intl Inc. director was just granted 500,000 options - June 8, 2022

Odyssey Group Intl Inc. director was just granted 500,000 options - June 8, 2022

Odyssey Group Intl Inc. director was just granted 500,000 options - June 8, 2022

Odyssey Group Intl: Odyssey Health, Inc. Announces Positive Results From Initial Phase I Clinical Trial Subjects For Concussion Drug - May 6, 2022

Entry into a Material Definitive - May 6, 2022

Odyssey Group Intl: Odyssey Health Welcomes United States Vice Admiral (R) Timothy Szymanski To Military Advisory Board - April 20, 2022

Entry into a Material Definitive - April 20, 2022

Entry into a Material Definitive - April 14, 2022

Odyssey Group Intl Inc. Just Filed Its Quarterly Report: Note 8.       Net Lo... - March 15, 2022

Entry into a Material Definitive - Feb. 18, 2022

Odyssey Group Intl: Odyssey Group International Receives Donation To Support A Treatment For Concussion And Forms Community Partnership With The Erase Ptsd Now Foundation - Jan. 10, 2022

Pursuant to the requirements of the Securities Exchange Act of - Dec. 30, 2021

On December - Dec. 27, 2021

Entry into a Material Definitive - Dec. 27, 2021

Odyssey Group Intl Inc. Just Filed Its Quarterly Report: Note 6. Net Loss Per... - Dec. 10, 2021

Other Material - Nov. 4, 2021

Odyssey Group Intl Inc. Just Filed Its Annual Report: Note 12. Subsequent ... - Oct. 29, 2021

Entry into a Material Definitive - Oct. 26, 2021

Entry into a Material Definitive - Oct. 26, 2021

Entry into a Material Definitive - Oct. 21, 2021

Odyssey Group Intl: Odyssey Group International Files Patent On Novel Breath-Propelled Nasal Delivery Device Odyssey Group International, Inc. (OTC: - Oct. 21, 2021

Odyssey Group International Files Patent On Novel Breath-Propelled Nasal Delivery Device - Oct. 19, 2021

Odyssey Group Intl: Odyssey Group International Begins Enrolling Subjects For - Sept. 24, 2021

Odyssey Group International Begins Enrolling Subjects for Phase 1 Clinical Trial to Treat Concussion - Sept. 22, 2021

Odyssey Group Intl Inc. director was just granted 500,000 restricted shares - Sept. 16, 2021

Odyssey Group Intl Inc. director was just granted 500,000 restricted shares - Sept. 16, 2021

Odyssey Group Intl Inc. director was just granted 500,000 restricted shares - Sept. 16, 2021

Submission of Matters to a Vote of Security - Sept. 15, 2021

Entry into a Material Definitive - Sept. 1, 2021

Odyssey Group Intl: Odyssey Group International Approved To Start Human Trial To Treat Concussion Odyssey Group International, Inc. (OTC: - Sept. 1, 2021

Odyssey Group International Approved to Start Human Trial to Treat Concussion         - Sept. 1, 2021

Odyssey Group International Completes Final Drug-Device Combination Product in Preparation for Clinical Trial Launch - Aug. 30, 2021

Odyssey Group International and Super Bowl MVPs Featured on “Banfield” Discussed Novel Concussion Treatment - Aug. 6, 2021

Odyssey Group Intl: Odyssey Group International Completes Ind-Enabling Studies, Submits Investigator’S Brochure For Phase 1 Clinical Trial Odyssey Group International, Inc. (OTC: - Aug. 6, 2021

Odyssey Group Intl Inc. releases salary data. CEO sees compensation rise 146% - Aug. 6, 2021

Odyssey Group International Completes IND-enabling Studies, Submits Investigator’s Brochure for Phase 1 Clinical Trial - Aug. 4, 2021

Tier Change - July 29, 2021

Odyssey Group International, Inc. Provides Notice of Annual Meeting of Stockholders - July 26, 2021

Preliminary Proxy Soliciting materials - July 26, 2021

On June - July 6, 2021

Odyssey Group International Reports Achieving Drug Safety Standards for Clinical Trials of its Drug for Treating Concussion - June 29, 2021

Odyssey Group Intl Inc. Just Filed Its Quarterly Report: Note 7.       Net L... - June 21, 2021

Notification of inability to timely file Form 10-Q or 10-QSB - June 14, 2021

Odyssey Group International Announces Successful Completion of Their Novel Nano-Particle Drug Formulation for Treating Concussion - June 2, 2021

Preliminary Proxy Soliciting materials - May 28, 2021

Odyssey Group International Announces Successful Toxicology Studies for its Concussion Drug - May 26, 2021

Odyssey Group International, Inc. Schedules Annual Meeting of Stockholders - May 24, 2021

Odyssey Group Intl Inc. director just declared 500,000 restricted shares - May 19, 2021

Odyssey Group International Welcomes Global Operations and Quality Leader Ricky Richardson to Board of Directors - May 13, 2021

Odyssey Group International Welcomes Dr Bob Arnot to Scientific Advisory Board - May 11, 2021

DEPARTURE OF DIRECTORS OR CERTAIN - May 10, 2021

Other preliminary proxy statements - May 7, 2021

Registration Withdrawal Request - April 21, 2021

Odyssey Group Intl Inc. director was just granted 1,000,000 options - April 9, 2021

Entry into a Material Definitive - April 7, 2021

Registration statement under Securities Act of 1933 - March 17, 2021

Sorry, no schedule available for this company

Odyssey Health, Inc. To Develop Intranasal Field- Deliverable Nerve Agent Antidote - Jan. 12, 2023

Odyssey Health, Inc. Provides a Year End Update on Company and Corporate Outlook for 2023 - Dec. 19, 2022

Odyssey Health, Inc. Provides Update on Company and the Progress of Concussion Drug Development - Nov. 23, 2022

Odyssey Health Inc. Files Full US Patent Application on Novel Breath-Propelled Intranasal Brain-Drug Delivery Device - Nov. 1, 2022

Odyssey Health, Inc. Forms Pharmaceutical Subsidiary Focused on Treating Neurological Diseases - Oct. 11, 2022

Odyssey Health, Inc. Provides Recap on Concussion Drug Development - Oct. 6, 2022

Odyssey Health, Inc. Makes Statement Regarding its Concussion Drug Development Program - Sept. 30, 2022

Odyssey Health, Inc. Announces Successful Completion of Phase I Clinical Trial for Concussion Drug - Sept. 28, 2022

Odyssey Health Achieves Positive Safety Outcomes for Concussion Drug in Multiple Ascending Dosing Trial - Aug. 18, 2022

NFL LEGEND BRETT FAVRE AND ODYSSEY HEALTH, INC. INVOLVED WITH HUMAN TRIALS OF FIRST DRUG TREATMENT FOR CONCUSSION - Feb. 11, 2022

Odyssey Group International Receives Donation to Support a Treatment for Concussion and forms Community Partnership with the Erase PTSD Now Foundation - Jan. 10, 2022

Odyssey Group International, Inc. Provides Notice of Annual Meeting of Stockholders - July 26, 2021

Odyssey Group International, Inc. Provides Notice of Annual Meeting of Stockholders - July 26, 2021

Odyssey Group International Reports Achieving Drug Safety Standards for Clinical Trials of its Drug for Treating Concussion - June 29, 2021

Odyssey Group International Reports Achieving Drug Safety Standards for Clinical Trials of its Drug for Treating Concussion - June 29, 2021

Odyssey Group International to Present at LD Micro Virtual Investor Conference - June 8, 2021

Odyssey Group International to Present at LD Micro Virtual Investor Conference - June 8, 2021

Odyssey Group International Announces Successful Completion of Their Novel Nano-Particle Drug Formulation for Treating Concussion - June 2, 2021

Odyssey Group International Announces Successful Completion of Their Novel Nano-Particle Drug Formulation for Treating Concussion - June 2, 2021

Odyssey Group International, Inc. Schedules Annual Meeting of Stockholders - May 24, 2021

 


Feedback